1 / 16

Prescription Medications

Prescription Medications. David L. Gee, PhD Professor of Food Science and Nutrition Central Washington University. Major Categories of Weight Loss Drugs. Appetite Suppressants Inhibitors of Nutrient Absorption (Metabolic Stimulants). Appetite Suppressants: Serotonergic Drugs.

salena
Télécharger la présentation

Prescription Medications

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prescription Medications David L. Gee, PhD Professor of Food Science and Nutrition Central Washington University

  2. Major Categories of Weight Loss Drugs • Appetite Suppressants • Inhibitors of Nutrient Absorption • (Metabolic Stimulants)

  3. Appetite Suppressants:Serotonergic Drugs • Mechanism of action • elevated levels of serotonin reduce appetite • Serotonin levels increase after eating • serotonergic drugs • Increase release of serotonin

  4. Serotonergic DrugsA shaky history • Fenfluramine • Dexfenfluramine (Redux) • 1997 FDA withdrew approval status • Heart valve damage • Primary pulmonary hypertension

  5. Appetite Suppresants:Noradrenergic Drugs • Mechanism of Action • elevation of norepinephrine • associated with satiety • Eating increases norepinephrine • noradrenergic drugs

  6. Noradrenergic Drugs • Phentermine • Phenylpropanolamine • Dexatrim, Acutrim, PPA • Also as decongestant in cold medications • OTC • FDA warnings ( 2004) • hemorrhagic stroke • removing PPA from all products

  7. Drugs that increase both serotonin and norepinephrine • Sibutramine (Meridia) • increases serotonin and norepinephrine by inhibiting their re-uptake • FDA approval 1997

  8. Sibutramine (Meridia) • Mean wt loss: 10-14 pounds • effects vary substantially • Side effects: • hypertension • dry mouth • headache • constipation • no sign of heart valve problems or PPH

  9. Sibutramine (Meridia) • FDA regulations • affect manufacturers’ advertisement/promotion • does NOT regulate how physicians prescribe • for obese clients (BMI>30) or • for overweight clients with health risks (BMI>27) • safe for one year use

  10. Combined Drug Treatment • fen/phen • fenfluramine/phenteramine • “off label use” • FDA: not tested for safety or effectiveness • Fenfluramine banned • Other combinations: • Ephedra-phenteramine

  11. Inhibitors of Nutrient Absorption • Orlistat (Xenical) • FDA approved 1999 • pancreatic lipase inhibitor • inhibits absorption of dietary fats • causes steatorrhea • may psychologically reduce fat/caloric intake

  12. Inhibitors of Nutrient Absorption • Dietary Supplements • Chitin (fat malabsorption) • Starch Blockers (alpha amylase inhibitors) • like all dietary supplements: • not tested for safety or effectiveness • not “approved” by FDA

  13. Metabolic Stimulants • Thyroid Hormone • only useful if TH deficient (rare) • results in significant LBM loss • Ephedra • dietary supplement • FDA investigating adverse effect claims • regulatory status in question

  14. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials.Int. J. Obesity & Related Met. Dis. 27:1437-1446 (2003) • RCT’s published between 1966-2002 • Double blind RCT of > 1 yr • BMI > 30 + comorbidities • Only two drugs w/ studies meeting these criteria • Orlistat/Xenical (11 studies, n=6021, mean BMI=35.7, predominantly white females) • Sibutramine/Meridia (3 studies, n=929, mean BMI=33.4, predominantly white females)

  15. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. • Orlistat (Xenical) • Mean weight loss = 2.7 kg • 2.9% greater than placebo • 12% lost > 10% of body weight • 33% attrition rate • Reductions in serum lipids, serum glucose, blood pressure, lower HDL-C • Gastro-intestinal side effects

  16. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. • Sibutramine (Meridia) • Mean weight loss = 4.3 kg • 4.6% wt loss • 15% lost > 10% of body weight • 48% attrition rate • Lower reductions in serum lipids than orlistat • Increased blood pressure and pulse rate

More Related